EYSINS, Switzerland, Oct. 28, 2013 /CNW/ - Biosafe is pleased to report
the launch of its new Smart-Max device at the ESH World Cord Blood
Congress in Monaco last week.
(Logo: http://photos.prnewswire.com/prnh/20131028/648200 )
The Smart-Max device has multiple areas of application in cell
processing, including cell mixing, cooling, thawing, dilution,
incubation and digestion. It is fully automated with an easy-to-use
touchscreen interface and can handle bags of various sizes.
Used in conjunction with Biosafe's Sepax cell separation system,
Smart-Max will bring further productivity gains to cellular product
In the cell therapy area, Sepax and Smart-Max together constitute an
integrated solution, which enables complete, controlled automation of
cell processing procedures, from storage to cell transplant
preparation. Point of care and biotechnology applications will also
benefit from this innovative technology.
Biosafe's CEO Olivier Waridel commented: "The Smart-Max demonstrates
Biosafe's commitment to ongoing innovation. Smart-Max completes the
already well-established Coolmix family of devices, by adding the
capability of thawing cellular products. With its versatility,
Smart-Max should find its place in every cell therapy facility."
Smart-Max is available now, subject to local regulatory approvals.
About the Biosafe Group
Founded in 1997 the Biosafe Group is active in the design, manufacture
and marketing of automated cell processing systems. Headquartered in
Switzerland and privately owned, the Biosafe Group operates through
regional subsidiaries (Geneva, Houston, Hong-Kong, Shanghai and Sao
Paulo) and is present in more than 45 countries, either directly or
SOURCE: Biosafe Group
For further information:
Biosafe Group SA